Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 1s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Evaluating the impact of pharmacogenomics on postoperative outcomes in cardiovascular surgery patients

Naina Bhoyar[1] , Himanshu Nirmal Chandu[2]

[1]Assistant Professor, Department of Pharmacy, Kalinga University, Raipur, India.
[2]Research Scholar, Department of Pharmacy, Kalinga University, Raipur, India.

Cite this paper as: Naina Bhoyar, Himanshu Nirmal Chandu, (2025). Evaluating the Impact of Pharmacogenomics on Postoperative Outcomes in Cardiovascular Surgery Patients. *Journal of Neonatal Surgery*, 14 (2), 95-101.

ABSTRACT

Cardiovascular disease (CVD) is the leading cause of death worldwide and is complex and mind-boggling. Overall, CVD is responsible for about one out of every four deaths. The phrase "cardiovascular disease" (CVD) often refers to a collection of fundamental, persistent abnormalities in the heart and veins that comprise the cardiovascular system. Therefore, with the correct drugs, these covering illnesses can be prevented or alleviated. Many prescriptions are commonly used since one medication is insufficient to treat a condition. Experts are forced to treat CVD aggressively due to the high rates of death and horror, which may cause severe drug reactions. At any rate, some people are unlikely to react favorably to the highest recommended dosage of the medication. Hereditary variation has been linked to the severity of illnesses such as circulatory strain and cholesterol levels, according to research on CVD.Pharmacogenomics holds potential for reducing adverse medication responses and increasing efficacy. It might significantly affect how cardiovascular disease is treated. With the creation of numerous pharmacogenetic tests over the last ten years, pharmacogenomics has evolved from the study of a single gene to genome-wide techniques. For cardiovascular pharmacogenomics to have the anticipated clinical impact, numerous obstacles must be removed. With an emphasis on adverse drug responses, pharmaceutical efficacy, recovery durations, and overall patient survival, this research paper assesses the effect of pharmacogenomics-guided treatment on postoperative outcomes.

Keywords: *Cardiovascular surgery, pharmacogenomics, pharmacogenetic testing.*

1. INTRODUCTION

One essential organ that helps pump blood through the veins to every part of the body is the heart. The myocardium has its own vein network known as the coronary or cardiovascular course to effectively provide these supplements to the phones of the heart wall because the blood supplements in the heart chambers cannot reach all the phone layers of the heart wall without assistance [2]. The right and left coronary veins of the ascending aorta supply oxygenated blood to the heart's myocardial. The front interventricular branch or left first falling (Chap) conduit supplies oxygenated blood to the ventricle walls. The circumflex route, a branch of the left coronary corridor, provides oxygenated blood to the left half of the heart's chamber and ventricle. The term "cardiovascular infections" (CVDs) refers to problems with the heart and veins [4]. One type of CVD is coronary heart disease (CHD). A unique pharmacogenetic profile may be present in each patient. Each person has a unique prescription reaction and weakness due to these genetic variations. Drugs rely on catalysts to reach their goal, provide therapeutic effects, and ultimately be eliminated from the body [13]. Because the properties encoding these molecules change dramatically, patients may have hyperactive, usual, or underactive catalysts [14]. As a result, no two people will have the same effects from the same medicine and dosage. Drug organization in the Periods convention ought to preferably be modified considering these differences [9]. The purpose of pharmacogenomic testing is specifically to enhance drug administration. Based on each patient's distinct genetic profile, the test results offer recommendations for the best medication to prescribe at the right dosage [5]. The cost-effectiveness of treatment is a significant factor in pharmacogenomics testing. In a survey of more than 68 different medications used in a wide range of clinical specialties, Verbelen et al. found that pharmacogenomics impacted treatment in either cost-prevailing or practical courses in the greater part of all reviews that reached a resolution for their medication [3]. SNPs (single-nucleotide polymorphisms) and CNVs (duplicate number varieties) are two hereditary variations of significance comparable to tranquilize reaction fluctuation that happen inside the human genome [8]. Present day pharmacogenomic testing oftentimes utilizes "per quality" testing for patient-explicit

outcomes appearing in danger inclinations for specific drugs since planning a full genome is tedious and asset requesting [7]. Nowadays, TPMT (thiopurine methyltransferase) and CYP2D6 quality tests are among the most frequently utilized in light of their moderateness and fast times required to circle back [11]. One more ongoing strategy to come by persistent explicit outcomes prior to involving in danger prescriptions with a standing for patient fluctuation is precautionary trying of various high-risk pharmacogenes [10].

Research Question

- What effects does pharmacogenomic profiling have on the treatment and recovery from atrial fibrillation in individuals having heart surgery?

2. METHODOLOGY

Proficient patients matured over 18 years determined to have CHD regardless of comorbidities were enlisted from both the long term and short-term divisions of cardiology. Pre-test and post-test plans were done for surveying the comprehensibility of PILs. Segment subtleties like comorbidities, age, sex, and instructive status were gotten from the patients. Kuppuswamy financial scale [65] was utilized for ascertaining the enlisted patients' financial status. The substance of PIL was approved by the master panel comprising of four specialists, four scholastic drug specialists, and one dietician. For the approval of PIL, agenda models were given to the master board of trustees. The essential changes in PIL were made in view of the idea of the advisory group prior to evaluating the lucidness [15]. The arranged and approved PILs in the English variant was meant Kannada and Malayalam dialects, utilizing forward and in reverse interpretation system; then, these pamphlets were likewise evaluated for clarity [16]. For client testing lucidness scores and client assessment scores enlightening factual investigation was performed. Matched understudy's t-test was utilized to dissect the scores with p esteem < 0.05 was viewed as genuinely critical [12].

Study design: The study included patients with coronary heart disease, with or without comorbidities, who were at least 18 years old. The study did not include patients with psychiatric illnesses or pregnant women with CHD.

Randomization: The inclusion criteria were evaluated based on the patient's records. Using the chit technique, patients who satisfied the inclusion requirements were randomized into interventional and control groups. A total of 290 chits were made, with the letters "C" and "I" on 145 chits each to represent the control and intervention groups, respectively, in order to randomly assign 290 patients into two groups. After being placed in a box, the chits were thoroughly mingled. Until the final 290th chit was also drawn out, they were drawn one after the other without swapping out the earlier ones. Lastly, there will be a 1:1 ratio of patients in the control and therapeutic groups.

Control group: During the trial period, participants in the control group received standard care from the cardiologist, nurse, and technicians. At the conclusion of the trial, these patients received pharmacological care services.

Interventional group: Patients having a place with the interventional bunch got common consideration notwithstanding the drug care administrations given by an examination researcher who is a certified drug specialist. Patients of this gathering got a very much planned redid PC plan in light of their medical issue which included prescription survey, patient training and guiding. The prescription audit process was completed to address the drug nonadherence issue. Patient advising and patient schooling were given in the nearby anguages (Kannada and Malayalam) with PILs at the hour of release. During the patient advising and training, the drug specialist underscored the distinctions between the ongoing meds and meds at the hour of release to further develop prescription adherence. Patients were directed and instructed with the PILs about CHD side effects, risk factors, analysis, diet, prescriptions, the significance of medicine adherence, potential medication related issues and way of life adjustments were given. Patients of this gathering were reached over phone on month to month premise to help them to remember their drug top off, the significance of prescription adherence and way of life adjustments.

Data Collection: Patient information were gathered in the wake of acquiring informed assent from the patients. The information was gathered in the information assortment structure contained orientation, progress in years, past clinical history, individual history, diet, family ancestry by alluding to patient's records during ward adjusts. Kuppuswamy financial scale [65] was utilized to evaluate the financial status.

1. OUTCOME MEASUREMENT

The primary outcomes will be the incidence of postoperative AF, which is defined as the development of new or recurrent AF within the first 30 days after surgery, and drug-related adverse events, such as bleeding complications or thromboembolic events, which may result from suboptimal anticoagulant or antiarrhythmic therapy. The length of hospital stay—shorter stays may imply better management and fewer complications—and mortality rates from cardiovascular disease and all causes will be secondary outcomes. The study will also evaluate healthcare resource consumption and expenditures, with a focus on any differences in pharmaceutical costs and hospital readmissions between the pharmacogenomic-guided and conventional care groups. The utilization of clinical documentation, follow-up visits, and patient self-reporting to measure these outcomes will

provide a comprehensive evaluation of the benefits of pharmacogenomic profiling in improving AF management and overall patient outcomes (figure 1).



Figure 1: Demographic profile of the patients

The FRE comprehensibility test scores were viewed as 61.5; this shows that the pre-arranged pamphlet is a standard one and it is not difficult to peruse and comprehend. FKGL test score was viewed as 7.4 affirming that the pre-arranged flyer can be perceived between the grade levels 7-8. Comprehensibility of Kannada, English, and Malayalam PILs were surveyed by client testing polls. Of the 86 PILs clients, Kannada flyer clients were viewed as more 40 (46.511%) trailed by English pamphlet clients 26 (30.23%), and Malayalam handout clients 20 (23.52). Client testing coherence mean score for generally handout client had fundamentally improved from 45 to 79.30. Complete client testing meaningfulness scores of Kannada, English, and Malayalam adaptations of PILs are portrayed in Figure 2.



Figure 2: Client testing intelligibility scores of PILs

The present study showed that the medication adherence rate was significantly improved p-value in the interventional group. The details of medication adherence rate at different intervals are presented in Figure 3.



Figure 3: Details of medication adherence rate at different intervals

One of the clinical outcomes measured, blood pressure significantly improved in the interventional group whereas, BMI, total cholesterol, blood sugar levels were improved clinically in the interventional group but not statistically significant. The details of clinical outcomes at different intervals are presented in Figure 4. The quality-of-life scores for physical, emotional and social domains were significantly improved in the interventional group.



Figure 4: Details of clinical outcomes at different intervals

In this study, we also assessed the influence of factors such as gender, educational status, comorbidities, lifestyle risk factor and food habits on PC outcomes such as medication adherence, clinical outcomes, and quality of life. It was observed that all the factors (groups) displayed an improvement in their level of medication adherence towards the end of the study. However, it was observed that gender, had a significant influence on clinical outcomes and quality of life. The female group showed a statistically significant improvement in clinical outcomes compared to males, although, two of the QoL scores namely MacNew Global and MacNew Physical domains were improved significantly among males.



Figure 5: Socio-demographic details of the CHD patients assessed for the association of diet and lipid profile

Out of 145 patients in the intervention group, 72 were found to be present with at least one life style risk factor. Among the 72 patients, males 69 (96%) presented a higher number of risk factors than females, 3(4%). It was observed that except gender, all other factors such as educational status, comorbidities, lifestyle risk factors, food habits did not have a significant influence on PC outcomes.



Figure 6: Association of gender, lifestyle, comorbidities and family history with diet among CHD patients

The female group showed a statistically significant improvement in clinical outcomes compared to males, although, two of the QoL scores namely MacNew Global and MacNew Physical domains were improved significantly among males.



Figure 7: Comparison of BMI and lipid profile levels in vegetarians and omnivorous

The present study showed that diet has a significant effect on lipids levels and we found omnivorous were associated with high levels of LDL, total cholesterol and other coronary heart disease risk factors compared to vegetarians. To assess the patient's condition, the pharmacists have to gather, synthesize and interpret the relevant information. In order to achieve this, effective communication must be developed with the patient, caregiver and other healthcare professionals. While assessing the patient, the pharmacist must obtain the patient's past medical history, medication history and lifestyle factors. This information can help predict the factors that influence the patient's risk of drug-related issues. An evaluation of the patient's prescription and medication chart includes talking to the patients, guardians or representatives and interviewing other health care professionals. Although the emphasis is on drug treatment issues, as the therapeutic approach is checked and approved, the procedure facilitates the detection of disease-related issues too. Lack of medication adherence and drug-related problems interfere with disease management's clinical outcomes, thereby indirectly increasing the patients' economic burden. Failure to adhere to medications due to lack of information on medicines use and drug-related problems is due to the near absence of medication review in hospitals. These problems can be reduced by implementing pharmaceutical care services and other healthcare members' services in disease management. Studies showed pharmaceutical care services like patient education and medication review improve the quality of life and clinical outcomes. However, the reach of pharmaceutical care services is minimal in India, unlike in developed countries therefore, the study has taken up to assess the impact of pharmaceutical care. There is a need to determine the extent of pharmaceutical care provided to patients, followed by the assessment of its impact.

3. CONCLUSION

The science of pharmacogenomics examines how a person's genes impact how they react to medications. Pharmacology, the science of drugs, and genomics, the study of genes and their activities, are combined in this subject to create safe, effective drugs that may be administered depending on a person's genetic composition. Despite the usefulness of pharmacogenomic testing, it is important to consider other important aspects that affect POP therapy. Under personalized medicine, patients should receive thorough care to guarantee an accurate and suitable analgesic strategy. People react differently to the same medication in this situation for a variety of reasons, such as differences in weight and behavior, sociocultural background, physiological function, and pharmacological interactions, such as metabolism and excretion. In addition, age and genetic differences play a significant role in how pain is perceived and managed. The need for lower dosages of analgesics like morphine is also associated with POP, which is less commonly reported among the elderly. This emphasizes how crucial it is to modify analgesic dosages, like morphine, for senior citizens, taking into account the influence of age-related variables on medication reactions. The promise of customizing diagnostic and therapeutic approaches to each patient's needs may be achievable, thanks to the success of pharmacogenomic research. Clinical guidelines that use genetic information to guide warfarin, clopidogrel, and statin therapy to lower the risk of toxicity are an intriguing example of this quick discovery stage. The time has come consuming and costly to execute these on a one case at a time case and patient-by-patient premise. The idea of prudently implanting DNA variety information in persistent records, to be utilized when an objective treatment is given, is beginning to be researched because of the falling expense of multiplexed genotyping. The adoption of this tailored strategy will depend on the mechanics and healthcare outcomes in such systems, current pharmacogenomics clinical trials, and ongoing genotype-phenotype link discoveries.

REFERENCES

[1] Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. JAMA surgery. 2017 Mar 1;152(3):292-8.

[2] Sumiati, Hendriyati P, Triayudi A, Yusta A, Syaefudin A. Classification of heart disorders using an artificial neural network approach. Journal of Internet Services and Information Security. 2024;14(2):189-201. https://doi.org/10.58346/JISIS.2024.I2.012

[3] Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?. The pharmacogenomics journal. 2017 Oct;17(5):395-402.

[4] Satish S, Herald AR. Fuzzy Attention U-Net Architecture Based Localization and YOLOv5 Detection for Fetal Cardiac Ultrasound Images. J Wirel Mob Netw Ubiquitous Comput. 2024;15(1):01-16. https://doi.org/10.58346/JOWUA.2024.I1.001

[5] Rani KP, Arshad M, Sangeetha A. Pothole Detection Using YOLO (You Only Look Once) Algorithm. In2022 International Conference on Advancements in Smart, Secure and Intelligent Computing (ASSIC) 2022 Nov 19 (pp. 1-6). IEEE. https://doi.org/10.70102/IJARES/V4S1/9

[6] Dunham WC, Weinger MB, Slagle J, Pretorius M, Shah AS, Absi TS, Shotwell MS, Beller M, Thomas E, Vnencak-Jones CL, Freundlich RE. CYP2D6 genotype-guided metoprolol therapy in cardiac surgery patients: rationale and design of the pharmacogenetic-guided metoprolol management for postoperative atrial fibrillation in cardiac surgery (PREEMPTIVE) pilot study. Journal of cardiothoracic and vascular anesthesia. 2020 Jan 1;34(1):20-8.

[7] Perera K, Wickramasinghe S. Design Optimization of Electromagnetic Emission Systems: A TRIZ-based Approach to Enhance Efficiency and Scalability. Association Journal of Interdisciplinary Technics in Engineering Mechanics. 2024 Mar 29;2(1):31-5.

[8] Hua ZL. Elucidating the Role of Cytochrome p450 Enzymes in Drug Metabolism and Interactions. Clinical Journal for Medicine, Health and Pharmacy. 2024 Sep 30;2(3):1-0.

[9] Arasuraja G. Organizational change management in digital transformation: a framework for success. Global Perspectives in Management. 2024;2(2):12-21.

[10] Peterson PE, Nicholson WT, Moyer AM, Arendt CJ, Smischney NJ, Seelhammer TG, Krecke CA, Haney RM, Yaw EJ, Chlan LL. Description of pharmacogenomic testing among patients admitted to the intensive care unit after cardiovascular surgery. Journal of Intensive Care Medicine. 2021 Oct;36(11):1281-5.

[11] Jobson MC, Subhashini R. Importance of neuropsychological rehabilitation on retraining cognitive functioning in school-going children with congenital heart disease (CHD). International Academic Journal of Humanities. 2016;3(2):117-122.

[12] Kukendrarajah K, Farmaki AE, Lambiase PD, Schilling R, Finan C, Schmidt AF, Providencia R. Advancing drug development for atrial fibrillation by prioritizing findings from human genetic association studies. EBioMedicine. 2024;105.

[13] Jalali Z, Rezaie H. Analyzing the effect of dynamic organizational capabilities (organizational learning) and knowledge management in achieving the objectives of health reform plan. Human Resource Management. 2016;3(12):1-4.

[14] Awad H, Ahmed A, Urman RD, Stoicea N, Bergese SD. Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery. Pharmacogenomics and Personalized Medicine. 2019 Jul 26:145-54.

[15] Mitropoulou C, Fragoulakis V, Bozina N, Vozikis A, Supe S, Bozina T, Poljakovic Z, Van Schaik RH, Patrinos GP. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke. Pharmacogenomics. 2015 Jan;16(2):137-48.

[16] Roberts JD, Chalazan B, Andrade JG, Macle L, Nattel S, Tadros R. Clinical Genetic Testing for Atrial Fibrillation: Are We There Yet?. Canadian Journal of Cardiology. 2024 Mar 28.